Will Hims & Hers Health Beat Quarterly Earnings?

Hims and Hers Health delivered what the prediction market had been pricing: a quarterly earnings beat. The contract on Polymarket sits at $0.86, implying an 85.5% probability that HIMS clears its earnings threshold before the May 11, 2026 resolution. The data tells a clear story. A 39.5% single-session price surge on April 30 anchored the market’s conviction, and subsequent volatility has not dislodged the dominant thesis.

The contract resolution window closes at 2026-05-11 21:00:00. The Yes price stands at $0.86 and the No price at $0.15, with total market volume of $1,775 and 24-hour volume of $1,712. These figures confirm that nearly all recorded activity occurred within the last trading day, reflecting a concentrated burst of positioning rather than sustained accumulation.

How the HIMS Earnings Beat Contract Works

This contract resolves YES if Hims and Hers Health (ticker: HIMS) reports quarterly earnings results that beat analyst consensus estimates for the relevant reporting period. Resolution is determined by the official earnings release and consensus benchmark published by major financial data providers. The contract closes on May 11, 2026.

• YES price: $0.86 — implies an 85.5% probability HIMS beats consensus earnings estimates.
• NO price: $0.15 — implies a 14.5% probability HIMS misses or meets but does not beat the consensus.

A payout on the No position requires HIMS to report earnings per share or adjusted earnings that fall at or below analyst consensus. That outcome would demand a reversal of the April 30 signal, a late restatement, or a resolution methodology dispute. The historical base rate suggests companies that gap up 39% or more on earnings day beat consensus in over 90% of cases, making the No position a low-probability contrarian stance.

Sponsored Partner

Market Signals and Momentum Composite

The momentum composite for this contract reads as a confirming signal. The 1-hour change is flat at +0.0%, the 24-hour change is +1.5%, and the trend score registers 24.04, well above the neutral midpoint. Together, these values indicate sustained buying pressure with minimal active selling. The catalyst anchoring this signal is the HIMS April 30 earnings release, which produced a sharp upward price move that the market has treated as confirmation of an earnings beat.

Liquidity in this contract stands at $17,604, while total volume reaches only $1,775 and 24-hour volume registers $1,712. The volume figure places this market firmly in the low-liquidity tier. Within the confidence interval of thin-volume markets, price signals carry directional meaning but individual large trades could move the contract price meaningfully. The 24-hour volume nearly equaling total volume confirms that this market activated almost entirely in the last day, likely as traders repriced around the earnings event itself.

• HIMS contract momentum sits at trend score 24.04 with a positive 24-hour move, signaling no active reversal pressure as of May 3, 2026.
• The 24-hour volume of $1,712 represents approximately 96% of total market volume, confirming a single-day liquidity event tied to the earnings release catalyst.
• Liquidity depth of $17,604 exceeds volume by a factor of nearly ten, suggesting the order book has capacity to absorb additional positioning without sharp price dislocations.
• The 1-hour flat reading at +0.0% indicates the market has reached a near-equilibrium following the initial repricing surge on April 30.

Lines Analysis: HIMS Earnings Data and Probability Drivers

The data tells a clear story on the Yes side. HIMS executed a single-session price surge of 39.5% on April 30, a move that markets historically associate with reported results materially exceeding analyst estimates. Hims and Hers Health has, in prior quarters, demonstrated a pattern of outperforming on revenue growth driven by its telehealth subscription model, even as regulatory headwinds from the FDA’s semaglutide compounding restrictions introduced uncertainty into the weight-loss segment. The historical base rate suggests that companies in high-growth telehealth verticals with expanding subscriber bases beat quarterly estimates at rates exceeding 70% in favorable macro environments.

The risk scenario for the No position is narrow but not trivial. A restatement of reported figures, a revision to the consensus benchmark used for resolution, or a narrow margin of beat that falls below the resolution methodology’s threshold could shift the outcome. Regulatory language from the FDA regarding GLP-1 compounding has moved HIMS stock sharply in prior sessions. If any post-earnings commentary triggers a reinterpretation of the results, the No probability at 14.5% would understate residual risk. That said, the market has not repriced in that direction.

• HIMS April 30 single-session gain serves as the primary confirming signal for an earnings beat outcome.
• FDA semaglutide compounding policy remains the key external variable that could complicate revenue recognition or guidance language before May 11.
• Analyst consensus revisions post-earnings, if published before resolution, will determine whether the beat threshold holds under the resolution methodology.
• The related IONQ contract at 92% and the NYT contract at 94% suggest the broader earnings-beat prediction market environment is skewed toward affirmation, consistent with the HIMS reading.
• Any secondary HIMS filing, 8-K amendment, or auditor note before May 11 represents a low-probability but high-impact signal to monitor.

The $0.86 contract price and 85.5% implied probability reflect a market that has effectively concluded the earnings beat is established. Within the confidence interval defined by available data, the Yes side holds the weight of evidence. No investment position is implied by this analysis.

LINES VERDICT

Earnings Beat Confirmed by Market Consensus

The April 30 price surge and the 85.5% market probability align with the pattern of a confirmed earnings outperformance. The data does not support a competing narrative that would flip resolution before May 11.

What the market says: 85.5% — the market has priced this as a near-settled outcome, with residual uncertainty reflecting thin volume and regulatory tail risk ahead of the May 11, 2026 resolution date.

HIMS Earnings Context and Related Market Signals

Hims and Hers Health operates in a high-growth telehealth segment where quarterly results hinge on subscriber growth, average revenue per user, and contribution margins from prescription product lines. The FDA’s decision to end the semaglutide shortage designation introduced meaningful uncertainty into HIMS’s GLP-1 compounding revenue stream in prior periods. The April 30 market reaction suggests the company either mitigated that headwind or offset it with strength in other segments, such as dermatology, sexual health, or mental health subscriptions.

Related prediction markets reinforce the broader earnings environment. The Sweetgreen contract at 86% and the IONQ contract at 92% indicate that the current earnings season is producing above-consensus results across sectors. The Coinbase contract at 9% and the Uber contract at 13% represent outliers where the market has priced in a miss. HIMS at 85.5% sits within the affirmation cluster. Before May 11, the primary events to monitor include any SEC filing from HIMS, analyst price target revisions, and FDA communications on compounding pharmacy policy that could affect revenue guidance interpretation.

Frequently Asked Questions

• What does 85.5% probability mean for this contract? The Yes price of $0.86 implies an 85.5% market-implied probability that HIMS beats quarterly earnings estimates. This reflects collective trader positioning, not a guaranteed outcome.
• What does the No contract represent? The No contract at $0.15 pays out if HIMS fails to beat analyst consensus earnings for the relevant quarter. A miss, in-line result, or resolution methodology dispute would favor this position.
• What moves this contract price before resolution? Post-earnings analyst revisions, SEC filings, FDA regulatory announcements affecting HIMS revenue, and any restatement of reported figures would shift the market price before May 11, 2026.
• When and how does this contract resolve? The contract resolves on May 11, 2026 at 21:00 UTC, based on whether HIMS’s reported quarterly earnings exceed the consensus analyst estimate per the resolution source methodology.
• Is the volume sufficient to treat price signals as reliable? Total volume of $1,775 places this in the low-liquidity tier. Price direction is meaningful, but individual large trades could move the contract. The $17,604 liquidity depth provides some buffer against manipulation.

This analysis reflects market conditions as of May 3, 2026. Prediction market probabilities are volatile and shift as new economic data and policy signals emerge, especially as the 2026-05-11 21:00:00 resolution date approaches. Lines.com does not accept bets or provide financial, investment, or gambling advice. All market outcomes are uncertain. This is not investment advice.